Alkem Laboratories Limited is a Mumbai-headquartered integrated pharmaceutical company that develops, manufactures and sells branded generics, generic formulations, APIs, biosimilars and nutraceuticals in India and internationally, supported by 18 manufacturing facilities, R&D centres and a growing subsidiary ecosystem (Enzene, Alkem MedTech, Ascend, Pharmacor and others).

Q3 FY26 results showed resilient performance: consolidated revenue of ₹37,368 million (+10.7% YoY), EBITDA ₹8,280 million at a 22.2% margin and PAT of ₹6,360 million, while international businesses grew 26.6% YoY led by the US and non‑US markets, signalling successful portfolio and geographic execution.

Strategic expansion into MedTech was announced via a binding term sheet to acquire majority stake in Occlutech, giving Alkem immediate presence in minimally invasive cardiac implants and a high‑value device pipeline, with management projecting Alkem MedTech to become a meaningful growth and margin contributor over the next 3–5 years.

R&D and pipeline depth are notable: Alkem disclosed 188 ANDA filings and 167 approvals (including tentative), ongoing NDAs/BLAs, Q3 R&D spend of ₹1,390 million (3.7% of sales) and planned GLP‑1 semaglutide domestic launch in March 2026, highlighting biologics and specialty chronic therapies as focus areas.

Balance sheet strength and regulatory progress underpin optionality: net cash of ₹55.9 billion as of Dec 31, 2025, multiple facilities with recent EIRs or clean inspection outcomes, and an active ANDA approval cadence that supports US growth and cross‑border expansion.